A live audio webcast of the presentation will be accessible from the Investors page of Albireo's website, www.albireopharma.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay on the Events and Presentations section of the Investors page of Albireo's website for at least two weeks following the event.
For additional information on the conference, visit https://www.bio.org/events/bio-ceo-investor-conference.
Albireo is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo's clinical pipeline includes two Phase 2 product candidates and one Phase 3 product candidate. Albireo was spun out from AstraZeneca in 2008.
Hans Vitzthum LifeSci Advisors, LLC. 212-915-2568 Media Contact: Heather Anderson6 Degrees 980-938-0260 email@example.com
News Provided by Acquire Media